Бессимптомная гиперурикемия: подходы к лечению в аспекте риска развития сердечно-сосудистых и почечных заболеваний

Бессимптомная гиперурикемия (ГУ) широко распространена в популяции. Данные многочисленных исследований подтверждают независимые ассоциации между повышением уровня мочевой кислоты и риском развития артериальной гипертонии, сердечно-сосудистых заболеваний, хронической болезни почек. ГУ рассматривается как независимый предиктор сердечно-сосудистой и общей смертности. Несмотря на активное изучение проблемы, до сих пор нет единых ответов на вопросы, касающиеся необходимости назначения уратснижающей терапии при бессимптомной ГУ, а результаты исследований по ее влиянию на исходы сердечно-сосудистых и почечных заболеваний противоречивы. В обзоре суммированы основные сведения по данному вопросу, накопленные к настоящему времени.

1. Stamp L, Dalbeth N. Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. Seminars in Arthritis and Rheumatism. 2017;46(4):457–64. DOI: 10.1016/j.semarthrit.2016.07.015

2. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT et al. Serum uric acid and the risk of cardiovascular and renal disease: Journal of Hypertension. 2015;33(9):1729–41. DOI: 10.1097/HJH.0000000000000701

3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018;36(10):1953– 2041. DOI: 10.1097/HJH.0000000000001940

4. Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. DOI: 10.15829/1560-4071-2020-3-3786

5. Perez-Ruiz F, Marimon E, Chinchilla SP. Hyperuricaemia with deposition: latest evidence and therapeutic approach. Therapeutic Advances in Musculoskeletal Disease. 2015;7(6):225–33. DOI: 10.1177/1759720X15599734

6. Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM et al. Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. Annals of Internal Medicine. 2018;169(8):535– 42. DOI: 10.7326/M18-1167

7. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12):1119–31. DOI: 10.1056/NEJMoa1707914

8. Feig DI, Soletsky B, Johnson RJ. Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension: A Randomized Trial. JAMA. 2008;300(8):924–32. DOI: 10.1001/jama.300.8.924

9. Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clinical and Experimental Nephrology. 2015;19(6):1044–53. DOI: 10.1007/s10157-015-1095-1

10. Shibagaki Y, Ohno I, Hosoya T, Kimura K. Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertension Research. 2014;37(10):919–25. DOI: 10.1038/hr.2014.107

11. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A et al. Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. Clinical Journal of the American Society of Nephrology. 2010;5(8):1388–93. DOI: 10.2215/CJN.01580210

12. Segal MS, Srinivas TR, Mohandas R, Shuster JJ, Wen X, Whidden E et al. The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic. Journal of the American Society of Hypertension. 2015;9(8):610-619.e1. DOI: 10.1016/j.jash.2015.05.009

13. Assadi F. Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension. Journal of Nephrology. 2014;27(1):51–6. DOI: 10.1007/s40620-013-0009-0

14. Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A et al. Allopurinol and Progression of CKD and Cardiovascular Events: Long-term Follow-up of a Randomized Clinical Trial. American Journal of Kidney Diseases. 2015;65(4):543–9. DOI: 10.1053/j.ajkd.2014.11.016

15. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of highdose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. The Lancet. 2010;375(9732):2161–7. DOI: 10.1016/S0140-6736(10)60391-1

16. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J et al. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015;131(20):1763–71. DOI: 10.1161/CIRCULATIONAHA.114.014536

17. Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H et al. Clinical Outcome of Hyperuricemia in IgA Nephropathy: A Retrospective Cohort Study and Randomized Controlled Trial. Kidney and Blood Pressure Research. 2012;35(3):153–60. DOI: 10.1159/000331453

18. Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clinical Endocrinology. 2015;83(4):475–82. DOI: 10.1111/cen.12673

19. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I et al. A Randomized Study of Allopurinol on Endothelial Function and Estimated Glomular Filtration Rate in Asymptomatic Hyperuricemic Subjects with Normal Renal Function. Clinical Journal of the American Society of Nephrology. 2011;6(8):1887–94. DOI: 10.2215/ CJN.11451210

20. Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S et al. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial. American Journal of Kidney Diseases. 2015;66(6):945–50. DOI: 10.1053/j.ajkd.2015.05.017

21. Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S et al. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. American Journal of Kidney Diseases. 2018;72(6):798–810. DOI: 10.1053/j.ajkd.2018.06.028

22. Agarwal V, Hans N, Messerli FH. Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta-Analysis. The Journal of Clinical Hypertension. 2013;15(6):435–42. DOI: 10.1111/j.1751-7176.2012.00701.x

23. Qu L, Jiang H, Chen J. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Annals of Medicine. 2017;49(2):142–56. DOI: 10.1080/07853890.2016.1243803

24. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, Allopurinol Use, and Heart Failure Outcomes. Archives of Internal Medicine. 2010;170(15):1358–64. DOI: 10.1001/archinternmed.2010.198

25. Hare JM, Mangal B, Brown J, Fisher C, Freudenberger R, Colucci WS et al. Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Journal of the American College of Cardiology. 2008;51(24):2301–9. DOI: 10.1016/j.jacc.2008.01.068

26. Синютина Е.А., Александрия Л.Г, Траянова Т.Г., Моисеев В.С. Гиперурикемия при хронической сердечной недостаточности. Кардиоренальные эффекты аллопуринола. Клиническая Нефрология. 2012;4:46-50

27. Zhang J, Dierckx R, Mohee K, Clark AL, Cleland JG. Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis. ESC Heart Failure. 2017;4(1):40–5. DOI: 10.1002/ehf2.12112

28. Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG et al. High-Dose Allopurinol Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease. Journal of the American College of Cardiology. 2013;61(9):926–32. DOI: 10.1016/j.jacc.2012.09.066

29. de Abajo FJ, Gil MJ, Rodríguez A, García-Poza P, Álvarez A, Bryant V et al. Allopurinol use and risk of non-fatal acute myocardial infarction. Heart. 2015;101(9):679–85. DOI: 10.1136/heartjnl-2014-306670

30. Larsen KS, Pottegård A, Lindegaard HM, Hallas J. Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study. The American Journal of Medicine. 2016;129(3):299-306. e2. DOI: 10.1016/j.amjmed.2015.11.003

31. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. New England Journal of Medicine. 2018;378(13):1200– 10. DOI: 10.1056/NEJMoa1710895

32. Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis & Rheumatology. 2018;70(11):1702–9. DOI: 10.1002/art.40583

33. Bubb MR. Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment–Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al. Arthritis & Rheumatology. 2019;71(8):1391–2. DOI: 10.1002/art.40914

34. Cuenca JA, Balda J, Palacio A, Young L, Pillinger MH, Tamariz L. Febuxostat and Cardiovascular Events: A Systematic Review and MetaAnalysis. International Journal of Rheumatology. 2019;2019:1076189. DOI: 10.1155/2019/1076189

35. Jansen TLThA, Janssen M. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation. Clinical Rheumatology. 2019;38(1):263–5. DOI: 10.1007/s10067-018-4396-4

36. Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. European Heart Journal. 2019;40(22):1778–86. DOI: 10.1093/eurheartj/ehz119

37. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrology. 2015;16(1):58. DOI: 10.1186/s12882-015-0047-z

38. Wang H, Wei Y, Kong X, Xu D. Effects of Urate-Lowering Therapy in Hyperuricemia on Slowing the Progression of Renal Function: A Meta-Analysis. Journal of Renal Nutrition. 2013;23(5):389–96. DOI: 10.1053/j.jrn.2012.08.005

39. Liu X, Zhai T, Ma R, Luo C, Wang H, Liu L. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Renal Failure. 2018;40(1):289–97. DOI: 10.1080/0886022X.2018.1456463

40. Su X, Xu B, Yan B, Qiao X, Wang L. Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis. PLOS ONE. 2017;12(11):e0187550. DOI: 10.1371/journal.pone.0187550

41. Елисеев М.С. Хроническая болезнь почек: роль гиперурикемии и возможности урат-снижающей терапии. Современная ревматология. 2018;12(1):60-5. DOI: 10.14412/1996-7012-2018-1-60-65

42. Borghi C, Tykarski A, Widecka K, Filipiak KJ, DomienikKarłowicz J, Kostka-Jeziorny K et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiology Journal. 2018;25(5):545–63. DOI: 10.5603/CJ.2018.0116

43. Чазова И.Е., Жернакова Ю.В., Кисляк О.А., Недогода С.В., Подзолков В.И., Ощепкова Е.В. и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019;16(4):8-21. DOI: 10.26442/2075082X.2019.4.190686

44. Carnovale C, Venegoni M, Clementi E. Allopurinol Overuse in Asymptomatic Hyperuricemia: A Teachable Moment. JAMA Internal Medicine. 2014;174(7):1031–2. DOI: 10.1001/jamainternmed.2014.1427